920501-77-5

Basic information

• Product Name: Cyclopropanamine, 1-(4-chloro-2-fluorophenyl)-
• Synonyms: Cyclopropanamine, 1-(4-chloro-2-fluorophenyl)-;1-(4-chloro-2-fluorophenyl)cyclopropan-1-amine
• CAS NO: 920501-77-5
• Molecular Formula: C9H9ClFN
• Molecular Weight: 0
• Mol File: 920501-77-5.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 239.7°C at 760 mmHg
• Flash Point: 98.8°C
• Appearance: /
• Density: 1.329g/cm³
• Vapor Pressure: 0.0396mmHg at 25°C
• Refractive Index: 1.582
• CAS DataBase Reference: Cyclopropanamine, 1-(4-chloro-2-fluorophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclopropanamine, 1-(4-chloro-2-fluorophenyl)-(920501-77-5)
• EPA Substance Registry System: Cyclopropanamine, 1-(4-chloro-2-fluorophenyl)-(920501-77-5)

Safety Data

• Hazardous Substances Data: 920501-77-5(Hazardous Substances Data)

Usage

InChI:InChI=1/C9H9ClFN/c10-6-1-2-7(8(11)5-6)9(12)3-4-9/h1-2,5H,3-4,12H2

Upstream product

• 925-90-6 ethylmagnesium bromide 
• 57381-51-8 4-chloro-2-fluorobenzonitrile 

Relevant articles and documents

Oxadiazole Amine Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same

The present invention relates to a novel compound having an activity of inhibiting histone deacetylase 6 (HDAC6), an optical isomer thereof or a pharmaceutically acceptable salt thereof, a use thereof for preparation of a drug for treatment, a pharmaceutical composition comprising the same, a treatment method using the composition, and a method for preparing the same. The novel compound, an optical isomer thereof or a pharmaceutically acceptable salt thereof according to the present invention has an activity of inhibiting histone deacetylase 6 (HDAC6), and is effective for preventing or treating HDAC6-related diseases, including infectious diseases; neoplasm; endocrine, nutritional and metabolic diseases; mental and behavior disorders; nerve disorders; eye and adnexa diseases; cardiovascular diseases; respiratory diseases; digestive organ diseases; skin and subcutaneous tissue diseases; musculoskeletal and connective tissue diseases; or congenital malformation, deformation and chromosomal abnormality.COPYRIGHT KIPO 2017